Catalyst Wire Dossier Catalyst Wire Dossier

BHV-3000 (Rimegepant) Orally Disintegrating Tablet

rimegepant · Pfizer
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BHV-3000 (Rimegepant) Orally Disintegrating Tablet, covering 2025-03-26 to 2025-03-26. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis [Phase 3]

See pricing